
Sign up to save your podcasts
Or


The first surge of IPO activity this year sees Alto Neuroscience, ArriVent Biopharma, CG Oncology, Kyverna Therapeutics and Metagenomi making announcements.
Lori, Greg and Tyler also discuss gene therapy pricing including Vertex/CRISPR's Casgevy.
By BioSpace4.9
1313 ratings
The first surge of IPO activity this year sees Alto Neuroscience, ArriVent Biopharma, CG Oncology, Kyverna Therapeutics and Metagenomi making announcements.
Lori, Greg and Tyler also discuss gene therapy pricing including Vertex/CRISPR's Casgevy.

90,994 Listeners

30,666 Listeners

43,528 Listeners

8,776 Listeners

970 Listeners

4,345 Listeners

1,170 Listeners

1,967 Listeners

56,508 Listeners

9,532 Listeners

337 Listeners

6,089 Listeners

6,564 Listeners

34 Listeners

23 Listeners